Infliximab Does Not Worsen Outcomes During Flare-ups Associated with Cytomegalovirus Infection in Patients with Ulcerative Colitis

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Inflammatory Bowel Diseases

• Publication date

  2015-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1097/MIB.0000000000000412PMID 25933392
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A model for identifying cytomegalovirus in patients with inflammatory bowel disease.

  2015cited by this paper
• Infliximab three-dose induction regimen in severe corticosteroid-refractory ulcerative colitis: early and late outcome and predictors of colectomy.

  2014cited by this paper
• Diagnosis and Treatment of Ulcerative Colitis with Cytomegalovirus Infection: Importance of Controlling Mucosal Inflammation to Prevent Cytomegalovirus Reactivation

  2014cited by this paper
• What are the factors that affect hospitalization and surgery for aggravation of ulcerative colitis?

  2014cited by this paper
• Long-term efficacy of infliximab for refractory ulcerative colitis: results from a single center experience

  2014cited by this paper
• Clinical utility of cytomegalovirus antigenemia assay and blood cytomegalovirus DNA PCR for cytomegaloviral colitis patients with moderate to severe ulcerative colitis.

  2014cited by this paper
• Anti-TNF alpha in the treatment of ulcerative colitis: a valid approach for organ-sparing or an expensive option to delay surgery?

  2014cited by this paper
• One‐year maintenance outcomes among patients with moderately‐to‐severely active ulcerative colitis who responded to induction therapy with adalimumab: subgroup analyses from ULTRA 2

  2013cited by this paper
• Therapeutic Drug Monitoring of Infliximab and Mucosal Healing in Inflammatory Bowel Disease: A Prospective Study

  2013cited by this paper
• Severe Disease Activity and Cytomegalovirus Colitis Are Predictive of a Nonresponse to Infliximab in Patients with Ulcerative Colitis

  2013cited by this paper
• Developments in the treatment of moderate to severe ulcerative colitis: focus on adalimumab

  2013cited by this paper
• Extracorporeal Photopheresis (ECP) in Patients with Steroid-dependent Crohn's Disease: An Open-label, Multicenter, Prospective Trial

  2013cited by this paper
• Establishment of a Novel Mouse Model of Ulcerative Colitis with Concomitant Cytomegalovirus Infection: In Vivo Identification of Cytomegalovirus Persistent Infected Cells

  2013cited by this paper
• Clinical use of anti-TNF therapy and increased risk of infections

  2013cited by this paper
• 52-Week Efficacy of Adalimumab in Patients with Moderately to Severely Active Ulcerative Colitis Who Failed Corticosteroids and/or Immunosuppressants

  2013cited by this paper
• Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 2: current management.

  2012cited by this paper
• Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease

  2012cited by this paper
• Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial.

  2012cited by this paper
• Second European evidence-based consensus on the diagnosis and management of ulcerative colitis part 1: definitions and diagnosis.

  2012cited by this paper
• Letter: mucosal PCR for cytomegalovirus in refractory ulcerative colitis

  2012cited by this paper
• Ulcerative colitis

  2012cited by this paper
• Prevalence of cytomegalovirus infection in steroid-refractory Crohn's disease.

  2012cited by this paper
• Management of cytomegalovirus infection in inflammatory bowel diseases.

  2012cited by this paper
• Cytomegalovirus Infection and the Gastrointestinal Tract

  2012cited by this paper
• Cytomegalovirus Load in Inflamed Intestinal Tissue Is Predictive of Resistance to Immunosuppressive Therapy in Ulcerative Colitis

  2011cited by this paper
• Review article: chronic viral infection in the anti‐tumour necrosis factor therapy era in inflammatory bowel disease

  2010cited by this paper
• Cytomegalovirus affects clinical outcome of infliximab in ulcerative colitis refractory to tacrolimus

  2010cited by this paper
• Cytomegalovirus Infection in Patients with Active Inflammatory Bowel Disease

  2010cited by this paper
• A Multicenter Experience With Infliximab for Ulcerative Colitis: Outcomes and Predictors of Response, Optimization, Colectomy, and Hospitalization

  2010cited by this paper
• TNF-alpha is an important pathogenic factor contributing to reactivation of cytomegalovirus in inflamed mucosa of colon in patients with ulcerative colitis: lesson from clinical experience.

  2010cited by this paper
• Cytomegalovirus Infection in Patients Who Required Colectomy for Toxic Megacolon or Severe Steroid-Refractory Ulcerative Colitis

  2010cited by this paper
• Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD‐subgroup analyses across four randomized trials

  2009cited by this paper
• Cytomegalovirus disappearance after treatment for refractory ulcerative colitis in 2 patients treated with infliximab and 1 patient with leukapheresis.

  2009cited by this paper
• Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease.

  2009cited by this paper
• Cytomegalovirus infection in ulcerative colitis: A prospective, comparative study on prevalence and diagnostic strategy

  2008cited by this paper
• Cytomegalovirus infection in inflammatory bowel disease patients undergoing anti-TNFalpha therapy.

  2008cited by this paper
• Usefulness of quantitative real‐time PCR assay for early detection of cytomegalovirus infection in patients with ulcerative colitis refractory to immunosuppressive therapies

  2007cited by this paper
• Infliximab and the risk of latent viruses reactivation in active Crohn's disease

  2007cited by this paper
• Cytomegalovirus infection in severe ulcerative colitis patients undergoing continuous intravenous cyclosporine treatment in Japan.

  2007cited by this paper
• Cytomegalovirus ileitis and hemophagocytic syndrome associated with use of anti-tumor necrosis factor-alpha antibody.

  2006cited by this paper
• Cytomegalovirus Colitis Complicating Inflammatory Bowel Disease

  2006cited by this paper
• Role for Tumor Necrosis Factor Alpha in Murine Cytomegalovirus Transcriptional Reactivation in Latently Infected Lungs

  2005cited by this paper
• Infliximab does not activate replication of lymphotropic herpesviruses in patients with refractory rheumatoid arthritis.

  2005cited by this paper
• Cytomegalovirus hepatitis associated with use of anti-tumor necrosis factor-alpha antibody.

  2005cited by this paper
• Cytomegalovirus Hepatitis Associated with Use of Anti-Tumor Necrosis Factor-α Antibody

  2005cited by this paper
• Cytomegalovirus Infection in Steroid-refractory Ulcerative Colitis: A Case-Control Study

  2004cited by this paper
• Cytomegalovirus retinitis in a patient treated with anti-tumor necrosis factor alpha antibody therapy for rheumatoid arthritis.

  2004cited by this paper
• Disseminated cytomegalovirus infection in Crohn's disease following anti-tumour necrosis factor therapy.

  2002cited by this paper
• A high prevalence of cytomegalovirus antigenaemia in patients with moderate to severe chronic plaque psoriasis: an association with systemic tumour necrosis factor α overexpression

  1999cited by this paper
• Interferon-gamma and tumor necrosis factor-alpha specifically induce formation of cytomegalovirus-permissive monocyte-derived macrophages that are refractory to the antiviral activity of these cytokines.

  1997cited by this paper
• ULCERATIVE colitis.

  1997cited by this paper
• Fibroblasts, epithelial cells, endothelial cells and smooth muscle cells are major targets of human cytomegalovirus infection in lung and gastrointestinal tissues.

  1995cited by this paper
• Cytomegalovirus reactivation and tumour necrosis factor.

  1994cited by this paper
• CYTOMEGALOVIRUS INFECTION IN TRANSPLANT RECIPIENTS THE ROLE OF TUMOR NECROSIS FACTOR

  1994cited by this paper
• [Ulcerative colitis].

  1958cited by this paper

• Extraintestinal Manifestations and Cytomegalovirus Reactivation Are Predictors of Difficult-To-Treat in Ulcerative Colitis

  2025cites this paper
• Cytomegalovirus Colitis in Adult Patients with Inflammatory Bowel Disease

  2025cites this paper
• Cytomegalovirus infection in patients with active ulcerative colitis: a prospective observational study.

  2025cites this paper
• Predictive Factors of Cytomegalovirus Colonic Reactivation in Patients with Active Ulcerative Colitis

  2025cites this paper
• Cytomegalovirus Infection in Adult Patients with Inflammatory Bowel Disease: A Literature Review

  2024cites this paper
• Cytomegalovirus Infection: An Underrated Target in Inflammatory Bowel Disease Treatment

  2023influential citation
• Serum Cytomegalovirus Polymerase Chain Reaction Test Is a Valuable Negative Predictor of Infection in Acute Severe Ulcerative Colitis

  2022cites this paper
• SARS-CoV-2 (COVID-19) pneumonia patient treated with two doses of infliximab within 2 weeks for acute severe ulcerative colitis

  2022cites this paper
• Prevalence of UL97 gene mutations and polymorphisms in cytomegalovirus infection in the colon associated with or without ulcerative colitis

  2021cites this paper
• Effects of tissue cytomegalovirus quantitative polymerase chain reaction in the management of ulcerative colitis flare-ups: Should we wave aside?

  2021cites this paper
• [Guideline for the Treatment and Prevention of Infections Associated with Immunosuppressive Therapy for Autoimmune Diseases].

  2021cites this paper
• Clinical Features and Therapeutic Outcomes of Post-colectomy Enteritis with Ulcerative Colitis

  2021cites this paper
• Risk Factors of Cytomegalovirus Reactivation in Ulcerative Colitis Patients: A Meta-Analysis

  2021cites this paper
• Viral infections in inflammatory bowel disease: Tips and tricks for correct management

  2021cites this paper
• Allogeneic expanded adipose‐derived mesenchymal stem cell therapy for perianal fistulas in Crohn’s disease: A case series

  2021cites this paper
• Cytomegalovirus Colitis in a Patient With Ulcerative Colitis

  2020cites this paper
• Increased incidence of systemic serious viral infections in patients with inflammatory bowel disease associates with active disease and use of thiopurines

  2020cites this paper
• Ulcerative Colitis and Cytomegalovirus Infection: From A to Z.

  2020cites this paper
• Current Diagnostic and Therapeutic Approaches to Cytomegalovirus Infections in Ulcerative Colitis Patients Based on Clinical and Basic Research Data

  2020cites this paper
• Cytomegalovirus and Inflammatory Bowel Diseases (IBD) with a Special Focus on the Link with Ulcerative Colitis (UC)

  2020cites this paper
• IgA, albumin, and eosinopenia as early indicators of cytomegalovirus infection in patients with acute ulcerative colitis

  2020cites this paper
• IgA, albumin, eosinopenia as early warning indicators for cytomegalovirus infection in patients with acute ulcerative colitis

  2020cites this paper
• Review article: managing the adverse events caused by anti‐TNF therapy in inflammatory bowel disease

  2019cites this paper
• A Practical Review of Cytomegalovirus in Gastroenterology and Hepatology

  2019cites this paper
• Detection of cytomegalovirus by immunohistochemistry of colonic biopsies and quantitative blood polymerase chain reaction: evaluation of agreement in ulcerative colitis

  2018cites this paper
• Polymerase chain reaction for detection of mucosal cytomegalovirus infection in patients with acute ulcerative colitis

  2018influential citation
• Infectious Complications of Biologics

  2018cites this paper
• CMV Infection in Pediatric IBD

  2018cites this paper
• Viral infections in the biologic therapy era

  2018cites this paper
• ESCMID Study Group for Infections in Compromised Hosts (ESGICH) Consensus Document on the safety of targeted and biological therapies: an infectious diseases perspective (Soluble immune effector molecules [I]: anti-tumor necrosis factor-α agents).

  2018cites this paper
• CASE REPORT

  2018cites this paper
• Short-Term and Long-Term Outcomes of Infliximab and Tacrolimus Treatment for Moderate to Severe Ulcerative Colitis: Retrospective Observational Study.

  2018cites this paper
• Regulatory role of NKG2D+ NK cells in intestinal lamina propria by secreting double-edged Th1 cytokines in ulcerative colitis

  2017cites this paper
• Approach to cytomegalovirus infections in patients with ulcerative colitis

  2017cites this paper
• The safety of biological pharmacotherapy for the treatment of ulcerative colitis

  2017cites this paper
• Cytomegalovirus, inflammatory bowel disease, and anti-TNFα

  2017cites this paper
• Cytomegalovirus in Ulcerative Colitis : Bystander or Leading

  2017cites this paper
• Corticosteroids and Thiopurines, But Not Tumor Necrosis Factor Antagonists, are Associated With Cytomegalovirus Reactivation in Inflammatory Bowel Disease: A Systematic Review and Meta-Analysis

  2017cites this paper
• Steroid-refractory inflammatory bowel disease is a risk factor for CMV infection.

  2016cites this paper
• Cytomegalovirus Colitis, Cytomegalovirus Hepatitis and Systemic Cytomegalovirus Infection: Common Features and Differences

  2016cites this paper
• Toward an Algorithm for the Diagnosis and Management of CMV in Patients with Colitis

  2016cites this paper
• Cytomegalovirus and ulcerative colitis: Place of antiviral therapy.

  2016cites this paper
• Targeting cytomegalovirus during ulcerative colitis flare-ups

  2016cites this paper